Cardiovascular disease affects one in four people—and the number is growing. We are developing specialized, highly innovative therapies to meet this need.
At PhaseBio, we are determined to overcome the lack of new treatment options for serious cardiovascular diseases and provide superior outcomes for patients and the healthcare system. We are driven by high-quality science, and we leverage our team’s deep expertise to rapidly develop a pipeline of unique medicines.
We use essential cookies to make our site work. These enable core functionality such as security and accessibility. Essential cookies are on by default. You can disable these by changing your browser settings, but this may affect how the website functions.
Google Analytics Cookies
We would like to set Google Analytics cookies to help us to improve our website by collecting and reporting information on how you use it. These cookies collect information in a way that does not directly identify anyone.